Dishman Carbogen Amics's quarterly market cap
declined
from Sep. 2025 (₹43,209 Mil) to Dec. 2025 (₹38,818 Mil) and
declined
from Dec. 2025 (₹38,818 Mil) to Mar. 2026 (₹20,377 Mil).
Dishman Carbogen Amics's annual market cap
declined
from Mar. 2024 (₹36,930 Mil) to Mar. 2025 (₹34,146 Mil) and
declined
from Mar. 2025 (₹34,146 Mil) to Mar. 2026 (₹20,377 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Dishman Carbogen Amics's Enterprise Value for Today is ₹47,184 Mil.
Dishman Carbogen Amics (NSE:DCAL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:DCAL vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Dishman Carbogen Amics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dishman Carbogen Amics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dishman Carbogen Amics's Market Cap distribution charts can be found below:
* The bar in red indicates where Dishman Carbogen Amics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Dishman Carbogen Amics's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dishman Carbogen Amics (NSE:DCAL) has a Market Cap of ₹26,732 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Dishman Carbogen Amics and its competitors. According to the industry distribution chart, Dishman Carbogen Amics ranks #533 out of 1428 companies in the Biotechnology industry, placing it in the top 37.3%.
Is Dishman Carbogen Amics' Market Cap too high?
Dishman Carbogen Amics' current Market Cap is ₹26,732 Mil. Based on the distribution chart, Dishman Carbogen Amics ranks #533 out of 1428 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Dishman Carbogen Amics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dishman Carbogen Amics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dishman Carbogen Amics ranks #533 out of 1428 companies for Market Cap. This puts Dishman Carbogen Amics in the upper half of its industry. The industry median Market Cap is 114.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Dishman Carbogen Amics and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dishman Carbogen Amics's current Market Cap is ₹26,732 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dishman Carbogen Amics stock overvalued right now?
Based on GuruFocus' analysis, Dishman Carbogen Amics (NSE:DCAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹236.12, compared to a current price of ₹170.02 — trading 28% below its estimated fair value. The current Market Cap is ₹26,732 Mil. Dishman Carbogen Amics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Dishman Carbogen Amics (NSE:DCAL), the current Market Cap is ₹26,732 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dishman Carbogen Amics (NSE:DCAL) Overvalued in 2026?
Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued.
The current stock price of ₹170.02 is trading 28% below its estimated GF Value™ of ₹236.12.
GuruFocus considers Dishman Carbogen Amics to be Modestly Undervalued.
Key valuation signals for NSE:DCAL:
Market Cap: ₹26,732 Mil
GF Value™: ₹236.12 vs. price of ₹170.02 (28% below fair value)
No single metric tells the full story. See the NSE:DCAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
71GF Score
Get the complete analysis for NSE:DCAL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DCAL has been successfully added to your 
